menu
    • menu
    [{"orgOrder":0,"company":"Five Prime Therapeutics","sponsor":"Seagen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Antibody-drug conjugate","moa":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Five Prime Therapeutics","amount2":0.29999999999999999,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0.29999999999999999,"dosageForm":"","sponsorNew":"Five Prime Therapeutics \/ Seattle Genetics","highestDevelopmentStatusID":"1","companyTruncated":"Five Prime Therapeutics \/ Seattle Genetics"},{"orgOrder":0,"company":"Five Prime Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Cabiralizumab","moa":"CSF1R","graph1":"Oncology","graph2":"Phase II","graph3":"Five Prime Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Five Prime Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Five Prime Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Five Prime Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Bemarituzumab","moa":"FGFR2B","graph1":"Oncology","graph2":"Phase III","graph3":"Five Prime Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Five Prime Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Five Prime Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Five Prime Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"FPA157","moa":"CCR8","graph1":"Oncology","graph2":"Preclinical","graph3":"Five Prime Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Five Prime Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Five Prime Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Five Prime Therapeutics","sponsor":"Cowen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Public Offering","leadProduct":"Bemarituzumab","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Five Prime Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"","sponsorNew":"Five Prime Therapeutics \/ Cowen","highestDevelopmentStatusID":"8","companyTruncated":"Five Prime Therapeutics \/ Cowen"},{"orgOrder":0,"company":"Five Prime Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"5 Fluorouracil","moa":"FGFR2B","graph1":"Oncology","graph2":"Phase II","graph3":"Five Prime Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Five Prime Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Five Prime Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Five Prime Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"5 Fluorouracil","moa":"FGFR2B","graph1":"Oncology","graph2":"Phase II","graph3":"Five Prime Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Five Prime Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Five Prime Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Five Prime Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"5-Fluorouracil","moa":"FGF","graph1":"Oncology","graph2":"Phase II","graph3":"Five Prime Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Five Prime Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Five Prime Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Five Prime Therapeutics","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Acquisition","leadProduct":"Bemarituzumab","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Phase III","graph3":"Five Prime Therapeutics","amount2":1.8999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":1.8999999999999999,"dosageForm":"Intravenous infusion","sponsorNew":"Five Prime Therapeutics \/ Amgen Inc","highestDevelopmentStatusID":"10","companyTruncated":"Five Prime Therapeutics \/ Amgen Inc"},{"orgOrder":0,"company":"Five Prime Therapeutics","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Acquisition","leadProduct":"Bemarituzumab","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Phase III","graph3":"Five Prime Therapeutics","amount2":1.8999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":1.8999999999999999,"dosageForm":"Intravenous infusion","sponsorNew":"Five Prime Therapeutics \/ Amgen","highestDevelopmentStatusID":"10","companyTruncated":"Five Prime Therapeutics \/ Amgen"}]

    Find Clinical Drug Pipeline Developments & Deals by Five Prime Therapeutics

    Menu

    Five Prime Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Five Prime Therapeutics

                            U.S.A arrow
                            Cosmoprof
                            Not Confirmed

                            Five Prime Therapeutics

                            U.S.A arrow
                            Cosmoprof
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bemarituzumab,Oxaliplatin,Calcium Folinate

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Amgen Inc

                            Deal Size : $1,900.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Amgen Successfully Completes Acquisition Of Five Prime Therapeutics

                            Details : Five Prime fits squarely within Amgen's leading oncology portfolio and includes bemarituzumab, a Phase 3 trial-ready, first-in-class program for gastric cancer, the third leading cause of cancer mortality worldwide.

                            Brand Name : FPA144

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            April 16, 2021

                            Lead Product(s) : Bemarituzumab,Oxaliplatin,Calcium Folinate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Amgen Inc

                            Deal Size : $1,900.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Five Prime Therapeutics

                            U.S.A arrow
                            Cosmoprof
                            Not Confirmed

                            Five Prime Therapeutics

                            U.S.A arrow
                            Cosmoprof
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bemarituzumab,Oxaliplatin,Calcium Folinate

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Amgen Inc

                            Deal Size : $1,900.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Amgen To Acquire Five Prime Therapeutics For $1.9 Billion in Cash

                            Details : Five Prime's lead asset, bemarituzumab, is a first-in-class, Phase 3 ready anti-FGFR2b antibody with positive data from a randomized, placebo-controlled Phase 2 study in frontline advanced gastric or gastroesophageal junction (GEJ) cancer.

                            Brand Name : FPA144

                            Molecule Type : Large molecule

                            Upfront Cash : $1,900.0 million

                            March 04, 2021

                            Lead Product(s) : Bemarituzumab,Oxaliplatin,Calcium Folinate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Amgen Inc

                            Deal Size : $1,900.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Five Prime Therapeutics

                            U.S.A arrow
                            Cosmoprof
                            Not Confirmed

                            Five Prime Therapeutics

                            U.S.A arrow
                            Cosmoprof
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bemarituzumab,Fluorouracil,Calcium Folinate

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Five Prime Therapeutics Presents Results of Phase 2 FIGHT Trial at ASCO GI

                            Details : The FIGHT trial evaluated bemarituzumab plus chemotherapy vs placebo plus chemotherapy in patients with fibroblast growth factor receptor 2b-positive , non HER2+ frontline advanced gastric or GEJ cancer. All three efficacy endpoints met pre-specified sta...

                            Brand Name : FPA144

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            January 15, 2021

                            Lead Product(s) : Bemarituzumab,Fluorouracil,Calcium Folinate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Five Prime Therapeutics

                            U.S.A arrow
                            Cosmoprof
                            Not Confirmed

                            Five Prime Therapeutics

                            U.S.A arrow
                            Cosmoprof
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bemarituzumab,Oxaliplatin,Fluorouracil

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Five Prime to Present Phase 2 FIGHT Trial Results of Bemarituzumab at ASCO Gastrointestinal Cancers Virtual An...

                            Details : FIGHT trial met all three efficacy endpoints with bemarituzumab in combination with mFOLFOX6 chemotherapy providing statistically significant and clinically meaningful improvements in progression-free survival, overall survival, and objective response ra...

                            Brand Name : FPA144

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            December 09, 2020

                            Lead Product(s) : Bemarituzumab,Oxaliplatin,Fluorouracil

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Five Prime Therapeutics

                            U.S.A arrow
                            Cosmoprof
                            Not Confirmed

                            Five Prime Therapeutics

                            U.S.A arrow
                            Cosmoprof
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bemarituzumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Cowen

                            Deal Size : $5.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Five Prime Announces Proposed Public Offering of Common Stock

                            Details : Five Prime plans to use the net proceeds of the offering to fund ongoing clinical development of bemarituzumab and FPT155, to advance FPA157 through preclinical and into clinical development, to advance its late-stage research programs and for working ca...

                            Brand Name : FPA144

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            November 11, 2020

                            Lead Product(s) : Bemarituzumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Cowen

                            Deal Size : $5.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Five Prime Therapeutics

                            U.S.A arrow
                            Cosmoprof
                            Not Confirmed

                            Five Prime Therapeutics

                            U.S.A arrow
                            Cosmoprof
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bemarituzumab,Oxaliplatin,Fluorouracil

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Five Prime Announces Bemarituzumab Plus Chemotherapy Demonstrates Significant Progression-Free and Overall Sur...

                            Details : All 3 efficacy endpoints in the Global Phase 2 FIGHT trial met pre-specified statistical significance. Bemarituzumab is a first-in-class therapeutic antibody targeting FGFR2b+ tumors found in approximately 30 percent of HER2- gastric cancers worldwide.

                            Brand Name : FPA144

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            November 10, 2020

                            Lead Product(s) : Bemarituzumab,Oxaliplatin,Fluorouracil

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Five Prime Therapeutics

                            U.S.A arrow
                            Cosmoprof
                            Not Confirmed

                            Five Prime Therapeutics

                            U.S.A arrow
                            Cosmoprof
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : FPA157

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Five Prime to Present First Preclinical Data of Anti-CCR8 Antibody FPA157 at Society for Immunotherapy of Canc...

                            Details : FPA157 is an antibody-dependent cell-mediated cytotoxicity (ADCC)-enhanced monoclonal antibody targeting CCR8 that is designed to deplete the T regulatory cell (Treg) population in the tumor microenvironment.

                            Brand Name : FPA157

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            November 02, 2020

                            Lead Product(s) : FPA157

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Five Prime Therapeutics

                            U.S.A arrow
                            Cosmoprof
                            Not Confirmed

                            Five Prime Therapeutics

                            U.S.A arrow
                            Cosmoprof
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bemarituzumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Five Prime Therapeutics Announces Publication of the Phase 1 Bemarituzumab Study

                            Details : Phase 1 data illustrates the therapeutic potential of bemarituzumab as a novel approach to treating patients with FGFR2b-overexpressing gastric and gastroesophageal junction adenocarcinoma (GEA).

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            March 13, 2020

                            Lead Product(s) : Bemarituzumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Five Prime Therapeutics

                            U.S.A arrow
                            Cosmoprof
                            Not Confirmed

                            Five Prime Therapeutics

                            U.S.A arrow
                            Cosmoprof
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Antibody-drug conjugate

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Seagen

                            Deal Size : $300.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Five Prime Grabs $5M lifeline in Seattle Genetics ADC deal

                            Details : Five Prime granted Seattle Genetics an exclusive worldwide license to a family of monoclonal antibodies and Seattle Genetics will be responsible for R&D manufacturing and marketing of ADC products.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : $5.0 million

                            February 19, 2020

                            Lead Product(s) : Antibody-drug conjugate

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Seagen

                            Deal Size : $300.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Five Prime Therapeutics

                            U.S.A arrow
                            Cosmoprof
                            Not Confirmed

                            Five Prime Therapeutics

                            U.S.A arrow
                            Cosmoprof
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cabiralizumab,Nivolumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Five Prime Therapeutics Provides Update on Phase 2 Trial of Cabiralizumab Combined with Opdivo® in Pancreatic...

                            Details : Phase 2 Trial of cabiralizumab plus opdivo (nivolumab) with and without chemotherapy in advanced pancreatic cancer did not meet primary endpoint.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            February 18, 2020

                            Lead Product(s) : Cabiralizumab,Nivolumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth